ICUI

ICU Medical, Inc. - Q1 2006 10-Q Summary

Business Context and Reporting Period

This filing is a Quarterly Report (Form 10-Q) for ICU Medical, Inc., covering the three-month period ended March 31, 2006. The company is a developer, manufacturer, and marketer of disposable medical devices, primarily for intravenous (I.V.) therapy and critical care applications. A significant portion of the business involves a 20-year Manufacturing, Commercialization and Development Agreement (MCDA) with Hospira, Inc., under which ICU Medical manufactures critical care products exclusively for Hospira.

Key Financial Metrics

Note: The company has no long-term debt. The "Finance loans receivable" listed on the balance sheet are assets (loans made by the company), not liabilities.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 80% year-over-year, driven primarily by the inclusion of sales under the MCDA with Hospira ($19.2 million in Q1 2006 vs. $0 in Q1 2005) and growth in custom I.V. systems.
• Margin Compression: Gross margin on net sales declined from 59.3% in Q1 2005 to 45.0% in Q1 2006. Management attributes this to the lower margins inherent in the new critical care products manufactured for Hospira under the MCDA.
• Expense Increases: Selling, General, and Administrative (SG&A) expenses rose 32% to $10.6 million due to compensation increases, bad debt expenses, and amortization related to the Salt Lake City facility. R&D expenses more than doubled to $1.6 million due to new product development.
• Customer Concentration: Sales to Hospira now represent 75% of total revenue (up from 61% in Q1 2005), increasing reliance on this single customer.

Guidance, Outlook, and Risks

• Outlook: Management expects gross margins to improve to 45-46% in the remainder of 2006 as manufacturing efficiencies are realized at the Salt Lake City plant. SG&A is expected to remain at 22-23% of revenue. Capital expenditures for 2006 are estimated at $13.5 million.
• Operational Shifts: The company is in the process of moving molding and automated assembly from San Clemente and Connecticut to Salt Lake City, and moving manual assembly to Mexico. These moves are expected to complete by early 2007.
• Key Risks:
  • Hospira Dependence: 75% of revenue comes from Hospira; any deterioration in this relationship or Hospira's market position poses a significant risk.
  • MCDA Performance: Profitability under the MCDA depends on achieving cost savings over Hospira's historical manufacturing costs. Failure to achieve these savings would adversely affect margins.
  • Relocation Risks: Moving manufacturing facilities carries risks of production interruptions, quality issues, and personnel retention challenges.
  • Competition: The company faces competition from larger firms (e.g., Cardinal Health/Alaris) and potential patent infringement challenges.

Investor Verification Checklist

• MCDA Margins: Verify if the company is meeting its cost-saving targets under the Hospira agreement to ensure projected margin recovery.
• Relocation Progress: Monitor the status of the manufacturing moves to Salt Lake City and Mexico for any production delays or quality control issues.
• Hospira Inventory Levels: Assess Hospira's inventory management to avoid the sharp sales declines experienced in 2004 due to inventory reductions.
• Patent Litigation: Track the status of ongoing patent infringement lawsuits against Alaris Medical Systems, which could impact future revenue or incur legal costs.
• International Growth: Evaluate the sustainability of the 65% year-over-year growth in international sales.